Our strengths_Elixir Clinical Research

CN|EN

Our Company Culture & Values Our Strengths Our Leadership

Clinical Operations Medical Services Regulatory Affairs Data Management Pharmacovigilance Biostatistics Real World Evidence Cardiac Safety Assessment

Patient Services

TrialNet Recruitment Platform Subject Service Platform

News Events Social Media

Find Your Passion Healthy Lifestyle Growth And Development Experienced Hire Campus Hire

Contact Information Online Message

|

CN

CN

EN

MENU

Our Strengths

Culture & Values

Patient-centered, digital transformation of clinical trials

Refined operation, excellent delivery

With years of experience and industry resources, Elixir Clinical Research has continuously improved the clinical informatization management level and data value mining ability, established an international delivery team, and enhanced the professional service ability to create higher value for clients.

Technology-based full service CRO

with innovative capability covering the whole life cycle of the product

Digital technology improves clinical study management and operation efficiency

Internal management

Digital operation system

eCooperate (CTMS)/Clinical Trial Management System
eArchives (eTMF)/Electronic Trial Master File management system
In-site and Insight Cloud (IIC)/Site think tank
electronic outcome assessment (eCOA)/Electronic patient-reported outcome system
eCollect (EDC)/Electronic data Captur system
eBalance (IWRS)/Randomization and Trial Supply Management

External connection

Digital solutions

iDCT/Remote intelligent clinical research platform
iRMS/ Randomization and Trial Supply Management
eTrial/Phase 1 ward system
eSite/Clinical research organization management system

Timely data entry and storage
SOPs and report template integration
Data-based risk management
Timely and compliant SAEs management
Intelligent and compliant document management
Transparent and straightforward trial process tracking

Average CRO industry working years for core business team members

Year

12 -
10 -
8 -
6 -
4 -
2 -
0 -

6

Medical Affairs
5

Biostastics
6

RWE
4

Data Management
8

Project Management
8

Regulatory Affairs
4

Clinical Operations
3

Pharmacovigilance

Our Project Experience

Note:The above information is updated until May 2022.

Project experience

Solid Tumor -

20%
Hematologic malignancies -

17%
Cardiovascular diseases -

9%
Respiratory tract inflammation -

9%
Nephrology -

7%
Dermatology -

5%
Ophthalmology -

5%
Urinary/Bladder -

6%
Other infectious diseases -

4%
Immune-mediated inflammatory diseases -

4%
Women's health -

2%
Antiviral therapy -

2%
Hematology -

2%
General hormones -

2%
Metabolic and cardiovascular risk -

2%
Psychiatric disorders -

2%
Cancer supportive care -

2%
- | 0
- | 2
- | 4
- | 6
- | 8
- | 10
- | 12
- | 14
- | 16
- | 18
- | 20

Project type

0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%

17%

Phase I & BE

9%

Phase II

18%

Phase III

43%

Phase IV & Postmarketing

22%

Phase IV &
Postmarketing

Sponsors

51%

49%

Domestic

Overseas

Contact Us

Please complete the form below to submit your request or questions.